U.S., March 11 -- ClinicalTrials.gov registry received information related to the study (NCT07459660) titled 'An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis' on March 05.
Brief Summary: ML-007C-MA-222 is a 52-week, flexible-dose, open-label extension study designed to evaluate the long-term safety, tolerability, and effectiveness of ML007C-MA in participants with ADP who have completed the antecedent study (ie, Study ML-007C-MA-221).
Study Start Date: March, 2026
Study Type: INTERVENTIONAL
Condition:
Psychosis Associated With Alzheimer's Disease
Intervention:
DRUG: ML-007C-MA
ML-007C-MA dosed as 105/1.5 mg BID or 210/3 mg BID
Recruitment Status: NOT_YET_RECRUITING
Sponsor: MapLight Therapeutics
Pub...